When clinical urologist Dr Christer Edlund witnessed the complete remission of terminal urothelial bladder cancer in a 65-year-old patient, some described it as a ‘medical miracle’. But at Ectin we don’t believe in ‘miracles’. We believe in research.
As that patient’s journey with cancer ended, our journey towards MFA-370, a novel therapy that aims to eliminate cancer tumors, began.
MFA-370 will be trialled first with a Phase I/II study for metastatic urothelial bladder cancer, a highly recurrent cancer that caused 200,000 deaths in 2020. Current treatment options can often inflict severe side effects. MFA-370 is planned to be a simple oral tablet offering the hope of improved quality of life during the most painful period of patients’ lives. In preclinical tests MFA-370 has eliminated prostate, breast and colorectal cancer cells too.
Ectin Research is committed to regular, transparent communication between ourselves, our investors and the wider business and scientific community.
MEET US at upcoming events and explore the latest presentations from our CEO Anna Sjöblom-Hallén at the link below.
Keep up to speed on developments with Ectin Research through our regularly updated FAQ page. Or subscribe to receive regular Financial Reports and Press Releases from us. (As members of Sweden’s Spotlight Stock Market all Ectin Research’s Investor communications are in Swedish.)
